INTELLIA THERAPEUTICS INC (NTLA): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy INTELLIA THERAPEUTICS INC (NTLA) following the 2026 Q1 hedge fund 13F filings?

As of today, NTLA has moved -9.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of -10.9%. Since the quarter end (March 31, 2026), NTLA gained -2.1% vs +0.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

INTELLIA THERAPEUTICS INC (NTLA)

301 + Investors. Track Smart Money conviction in NTLA. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — NTLA

Based on 302 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added NTLA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

302 hedge funds hold NTLA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q

+12 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟢

More buyers than sellers — 63% buying

194 buying114 selling

Last quarter: 194 funds were net buyers (62 opened a brand new position + 132 added to an existing one). Only 114 were sellers (62 trimmed + 52 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 40 → 49 → 69 → 62. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

55% of holders stayed for 2+ years

■ 55% conviction (2yr+) ■ 23% medium ■ 22% new

167 out of 302 hedge funds have held NTLA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +51% but shares only +7% — price-driven

Value

+50%

+7%

Last quarter: the total dollar value of institutional holdings rose +51%, but actual share count only changed +7%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

📈

Growing discovery — still being found

50 → 40 → 49 → 69 → 62 new funds/Q

New funds entering each quarter: 40 → 49 → 69 → 62. A growing number of institutions are discovering NTLA each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Deep conviction — 64% of holders stayed 2+ years

■ 64% veterans ■ 13% 1-2yr ■ 23% new

Of 315 current holders: 201 (64%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.

✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds

49 of 302 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.6

out of 10

Low Exit Risk

Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	301	292	3.08%
13F Shares	117M	109M	7.11%
Total Value	$1.48B	$980M	50.86%
New Positions	61	69	-8
Increased Positions	129	97	+32
Closed Positions	52	58	-6
Reduced Positions	59	87	-28
Total Calls	12	17	-29.41%
Total Puts	6	9	-33.33%
PUT/CALL Ratio	0.5	0.53	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

301

292

3.08%

13F Shares

117M

109M

7.11%

Total Value

$1.48B

$980M

50.86%

New Positions

-8

Increased Positions

129

+32

Closed Positions

-6

Reduced Positions

-28

Total Calls

-29.41%

Total Puts

-33.33%

PUT/CALL Ratio

0.5

0.53

Bullish

Institutional Holders (2026 Q1)

301 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NTLA. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 institutional holders of NTLA — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	REGENERON PHARMACEUTICALS, INC.	99.14%	3,702,995	$47.5M
2	Birchview Capital, LP	3.25%	445,400	$5.7M
3	ARK Investment Management LLC	1.45%	14,509,247	$186.0M
4	Contrarius Group Holdings Ltd	1.39%	1,911,839	$24.5M
5	Orchard Capital Management, LLC	1.10%	82,030	$1.1M
6	IQ EQ FUND MANAGEMENT (IRELAND) Ltd	0.71%	724,286	$9.3M
7	Canal Insurance CO	0.63%	230,000	$3K
8	DIADEMA PARTNERS LP	0.44%	200,000	$2.6M
9	HIMENSION CAPITAL (SINGAPORE) PTE. LTD.	0.42%	429,540	$5.5M
10	Opaleye Management Inc.	0.41%	245,000	$3.1M
11	Torrey Growth & Income Advisors	0.37%	70,547	$886K
12	Elmwood Wealth Management, Inc.	0.36%	102,924	$1.3M
13	Amova Asset Management Americas, Inc.	0.36%	1,973,061	$25.3M
14	Casdin Capital, LLC	0.34%	355,000	$4.6M
15	Generali Investments Towarzystwo Funduszy Inwestycyjnych	0.26%	40,000	$513K
16	PSP Research LLC	0.24%	26,900	$345K
17	Avidity Partners Management LP	0.23%	75,000	$1.0M
18	Gen-Wealth Partners Inc	0.19%	47,176	$605K
19	Green Alpha Advisors, LLC	0.18%	14,167	$182K
20	Scientech Research LLC	0.17%	16,265	$209K
21	Havemeyer Place LP	0.16%	109,439	$1.4M
22	AlphaCentric Advisors LLC	0.15%	11,506	$148K
23	IvyRock Asset Management (HK) Ltd	0.14%	19,830	$254K
24	Intellectus Partners, LLC	0.14%	54,475	$698K
25	GSA CAPITAL PARTNERS LLP	0.14%	178,301	$2K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — INTELLIA THERAPEUTICS INC (NTLA)

What does the Smart Money Trend signal show for NTLA?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added NTLA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NTLA?

More buyers than sellers — 63% buying: Last quarter: 194 funds were net buyers (62 opened a brand new position + 132 added to an existing one). Only 114 were sellers (62 trimmed + 52 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NTLA holders?

Strong quality — 38% AUM from major funds: 49 of 302 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NTLA?

55% of holders stayed for 2+ years: 167 out of 302 hedge funds have held NTLA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy INTELLIA THERAPEUTICS INC (NTLA) following the 2026 Q1 hedge fund 13F filings?

As of today, NTLA has moved -9.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of -10.9%. Since the quarter end (March 31, 2026), NTLA has gained -2.1% vs +0.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

INTELLIA THERAPEUTICS INC (NTLA)

Smart Money Signals — NTLA

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Steady growth — +4% more funds vs a year ago

More buyers than sellers — 63% buying

Fewer new buyers each quarter (-7 vs last Q)

55% of holders stayed for 2+ years

Value +51% but shares only +7% — price-driven

Growing discovery — still being found

Deep conviction — 64% of holders stayed 2+ years

Strong quality — 38% AUM from major funds

Institutional Sentiment Summary — NTLA

Hedge Fund Ownership: NTLA

Market Analysis: NTLA

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: NTLA

Is It Too Late to Buy INTELLIA THERAPEUTICS INC (NTLA) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: NTLA

Statistics: NTLA

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — INTELLIA THERAPEUTICS INC (NTLA)

Welcome to 13Foresight!